# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 05-15-2024 | 03-31-2024 | 10-Q | |
2 | 04-01-2024 | 12-31-2023 | 10-K | |
3 | 11-20-2023 | 09-30-2023 | 10-Q | |
4 | 08-25-2023 | 06-30-2023 | 10-Q |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The efficacy and safety of tafenoquine in treating human babesiosis will be evaluated in a randomized, double-blind, placebo-co...
With the tafenoquine for acute babesiosis orphan drug designation, 60 Degrees Pharmaceuticals now qualifies for certain incenti...
HC Wainwright & Co. analyst Edward White reiterates 60 Degrees (NASDAQ:SXTP) with a Neutral.
60 Degrees Pharmaceuticals has entered an agreement with Tufts Medical Center to conduct a clinical trial that will evaluate th...